Skip to main content

Safety, tolerability and immunogenicity of VAQTA given concomitantly versus nonconcomitantly with other pediatric vaccines in healthy 12-month-old children.

Publication ,  Journal Article
Guerra, FA; Gress, J; Werzberger, A; Reisinger, K; Walter, E; Lakkis, H; Grosso, AD; Welebob, C; Kuter, BJ; Pediatric Study Group for VAQTA
Published in: Pediatr Infect Dis J
October 2006

BACKGROUND: The objective of this study is to assess whether hepatitis A vaccine is immunogenic and well tolerated when administered to 12-month-old children alone or concomitantly with other routinely administered pediatric vaccines. METHODS: Six hundred seventeen healthy 12-month-old children were randomized to receive dose 1 of hepatitis A vaccine given alone or concomitantly with measles-mumps-rubella vaccine and varicella vaccine and dose 2 of hepatitis A vaccine given alone or concomitantly with diphtheria-tetanus-acellular pertussis vaccine and optionally with oral or inactivated poliovirus vaccine. Participants were followed for clinical adverse experiences and serologic responses to all vaccine antigens. Antibody responses were compared with historical controls for some indices. RESULTS: The safety profile was generally comparable whether hepatitis A vaccine was administered alone or concomitantly with other vaccines. When administered alone, the hepatitis A seropositivity rate was 98.3% and 100% for dose 1 and dose 2, respectively, and after dose 2 was similar to historical rates and the geometric mean titers were similar between initially seropositive and initially seronegative subjects (6207 and 6810 mIU/mL, respectively). After concomitant administration with hepatitis A vaccine, antibody responses to measles, mumps, rubella, diphtheria, tetanus and filamentous hemagglutinin (98.8%, 99.6%, 100%, 98.6%, 100% and 83.3%, respectively) were similar to historical controls and response to poliovirus was demonstrated, but immune responses to varicella zoster virus (79%) and pertussis toxoid (76%) were inferior to historical controls. CONCLUSIONS: Hepatitis A vaccine is highly immunogenic and generally well tolerated when administered to healthy children as young as 12 months of age regardless of initial hepatitis A serostatus and can be administered concomitantly with measles-mumps-rubella vaccine and oral or inactivated poliovirus vaccine.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Pediatr Infect Dis J

DOI

ISSN

0891-3668

Publication Date

October 2006

Volume

25

Issue

10

Start / End Page

912 / 919

Location

United States

Related Subject Headings

  • Poliovirus Vaccine, Oral
  • Poliovirus Vaccine, Inactivated
  • Pediatrics
  • Measles-Mumps-Rubella Vaccine
  • Male
  • Infant
  • Immunoenzyme Techniques
  • Immunization Schedule
  • Humans
  • Hepatitis A Vaccines
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Guerra, F. A., Gress, J., Werzberger, A., Reisinger, K., Walter, E., Lakkis, H., … Pediatric Study Group for VAQTA. (2006). Safety, tolerability and immunogenicity of VAQTA given concomitantly versus nonconcomitantly with other pediatric vaccines in healthy 12-month-old children. Pediatr Infect Dis J, 25(10), 912–919. https://doi.org/10.1097/01.inf.0000238135.01287.b9
Guerra, Fernando A., Jacqueline Gress, Alan Werzberger, Keith Reisinger, Emmanuel Walter, Hassan Lakkis, Anthony D. Grosso, Carolee Welebob, Barbara J. Kuter, and Pediatric Study Group for VAQTA. “Safety, tolerability and immunogenicity of VAQTA given concomitantly versus nonconcomitantly with other pediatric vaccines in healthy 12-month-old children.Pediatr Infect Dis J 25, no. 10 (October 2006): 912–19. https://doi.org/10.1097/01.inf.0000238135.01287.b9.
Guerra FA, Gress J, Werzberger A, Reisinger K, Walter E, Lakkis H, et al. Safety, tolerability and immunogenicity of VAQTA given concomitantly versus nonconcomitantly with other pediatric vaccines in healthy 12-month-old children. Pediatr Infect Dis J. 2006 Oct;25(10):912–9.
Guerra, Fernando A., et al. “Safety, tolerability and immunogenicity of VAQTA given concomitantly versus nonconcomitantly with other pediatric vaccines in healthy 12-month-old children.Pediatr Infect Dis J, vol. 25, no. 10, Oct. 2006, pp. 912–19. Pubmed, doi:10.1097/01.inf.0000238135.01287.b9.
Guerra FA, Gress J, Werzberger A, Reisinger K, Walter E, Lakkis H, Grosso AD, Welebob C, Kuter BJ, Pediatric Study Group for VAQTA. Safety, tolerability and immunogenicity of VAQTA given concomitantly versus nonconcomitantly with other pediatric vaccines in healthy 12-month-old children. Pediatr Infect Dis J. 2006 Oct;25(10):912–919.

Published In

Pediatr Infect Dis J

DOI

ISSN

0891-3668

Publication Date

October 2006

Volume

25

Issue

10

Start / End Page

912 / 919

Location

United States

Related Subject Headings

  • Poliovirus Vaccine, Oral
  • Poliovirus Vaccine, Inactivated
  • Pediatrics
  • Measles-Mumps-Rubella Vaccine
  • Male
  • Infant
  • Immunoenzyme Techniques
  • Immunization Schedule
  • Humans
  • Hepatitis A Vaccines